Genetix delivers strong 2025 revenue growth resulting in the Company’s first ever profitable quarterIn 2025, >100 U.S. patients were treated and >150 U.S. patients completed their first cell ...

Haunted by the cystic fibrosis patients he could not help, one Iowa doctor commits his life to understanding what is broken deep inside their cells.

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

This article examines how cultivated fat has the potential to bridge the gap between plant-based analogs and authentic animal tissue.

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma. At a live Case-Based Roundtable event during the 2025 American Society of ...

Albemarle Corporation stock outlook: lithium cycle risks, valuation vs SQM, and long-term thesis. Click for more on ALB stock ...

This week，the solid-state battery industry showed a dual-engine momentum driven by "intensive breakthroughs on the technology front and targeted solutions on the policy front." CATL disclosed a ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

NIO Inc. ( NIO) Q4 2025 Earnings Call March 10, 2026 8:00 AM EDT Hello, ladies and gentlemen. Thank you for standing by for NIO Inc.'s Fourth Quarter and Full Year 2025 Earnings Conference Call.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and ...